Mouse Anti-DGKE Recombinant Antibody (7E1) (CBMAB-D0787-YC)

Name: Mouse Anti-DGKE Recombinant Antibody (7E1)
SKU: CBMAB-D0787-YC
Rating: 5 (1 reviews)

See all DGKE antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

7E1

Application

ELISA, WB

Immunogen

DGKE (NP_003638, 141 a.a. ~ 240 a.a) partial recombinant protein with GST tag. The immunogen sequence: CKQQCGCQPK LCDYRCIWCQ KTVHDECMKN SLKNEKCDFG EFKNLIIPPS YLTSINQMRK DKKTDYEVLA SKLGKQWTPL IILANSRSGT NMGEGLLGEF

Specificity

Human

Antibody Isotype

IgG3, λ

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage

Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Epitope

aa 141-240

More Infomation

Target

Full Name

diacylglycerol kinase, epsilon 64kDa

Introduction

Diacylglycerol kinases are thought to be involved mainly in the regeneration of phosphatidylinositol (PI) from diacylglycerol in the PI-cycle during cell signal transduction. When expressed in mammalian cells, DGK-epsilon shows specificity for arachidonyl-containing diacylglycerol. DGKE is expressed predominantly in testis.

Entrez Gene ID

8526

UniProt ID

P52429

Alternative Names

Diacylglycerol Kinase Epsilon; Diacylglycerol Kinase, Epsilon 64kDa; Diglyceride Kinase Epsilon; DAG Kinase Epsilon; EC 2.7.1.107; DGK-Epsilon; DAGK5;

Function

Membrane-bound diacylglycerol kinase that converts diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and regulates the respective levels of these two bioactive lipids (PubMed:15544348, PubMed:19744926, PubMed:22108654, PubMed:21477596, PubMed:23949095).

Thereby, acts as a central switch between the signaling pathways activated by these second messengers with different cellular targets and opposite effects in numerous biological processes (PubMed:8626589, PubMed:15544348).

Also plays an important role in the biosynthesis of complex lipids (PubMed:8626589).

Displays specificity for diacylglycerol substrates with an arachidonoyl acyl chain at the sn-2 position, with the highest activity toward 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol the main diacylglycerol intermediate within the phosphatidylinositol turnover cycle (PubMed:19744926, PubMed:22108654, PubMed:23274426).

Can also phosphorylate diacylglycerol substrates with a linoleoyl acyl chain at the sn-2 position but much less efficiently (PubMed:22108654).

Biological Process

Diacylglycerol metabolic process Source: UniProtKB
Intracellular signal transduction Source: GO_Central
Lipid phosphorylation Source: UniProtKB
Modulation of chemical synaptic transmission Source: Ensembl
Phosphatidic acid biosynthetic process Source: UniProtKB
Phosphatidylinositol biosynthetic process Source: Ensembl
Platelet activation Source: Reactome
Protein kinase C-activating G protein-coupled receptor signaling pathway Source: InterPro

Cellular Location

Cytoplasm; Membrane

Involvement in disease

Nephrotic syndrome 7 (NPHS7):
A form of nephrotic syndrome, a renal disease clinically characterized by severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. NPHS7 is an autosomal recessive form characterized by onset of proteinuria usually in the first decade of life. The disorder is progressive, and some patients develop end-stage renal disease within several years. Renal biopsy typically shows membranoproliferative glomerulonephritis.
Hemolytic uremic syndrome atypical 7 (AHUS7):
An atypical form of hemolytic uremic syndrome characterized by acute onset in the first year of life of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. After the acute episode, most patients develop chronic renal insufficiency. Unlike other genetic forms of aHUS, AHUS7 is not related to abnormal activation of the complement system.

Alabdulqader, M., & Alfakeeh, K. (2021). A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report. BMC nephrology, 22(1), 1-5.

Koyun, M., Aksoy, G. K., Çomak, E., Özaltın, F., & Akman, S. (2021). Outcome of diacylglycerol kinase epsilon–mediated hemolytic uremic syndrome in an infant. Kidney International, 99(6), 1500-1501.

Liu, D., Ding, Q., Dai, D. F., Padhy, B., Nayak, M. K., Li, C., ... & Attanasio, M. (2021). Loss of diacylglycerol kinase ε causes thrombotic microangiopathy by impairing endothelial VEGFA signaling. JCI insight, 6(9).

Fu, W., Li, M., Lin, H., Xu, Y., Han, W., Chen, H., & Sun, L. (2021). Cyclosporine A relieved proteinuria and hypoproteinemia in DGKE nephropathy. Clinica Chimica Acta, 518, 78-82.

Brocklebank, V., Kumar, G., Howie, A. J., Chandar, J., Milford, D. V., Craze, J., ... & Kavanagh, D. (2020). Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney international, 97(6), 1260-1274.

Holanda, M. I. D., Gomes, C. P., Araujo, S. D. A., Wanderley, D. C., Eick, R. G., Dantas, G. C., ... & Palma, L. M. P. (2019). Diacylglycerol kinase epsilon nephropathy: late diagnosis and therapeutic implications. Clinical kidney journal, 12(5), 641-644.

Sharma, A., Khandelwal, P., Yadav, M., Sethi, S., Hari, P., Sinha, A., & Bagga, A. (2019). Atypical hemolytic uremic syndrome with diacylglycerol kinase epsilon (DGKE) gene mutation. Asian Journal of Pediatric Nephrology, 2(2), 101.

So, V., Wu, J., Traynor-Kaplan, A., Choy, C., Epand, R., Botelho, R., & Lemaire, M. (2019). Phosphatidylinositol cycle disruption is central to atypical hemolytic-uremic syndrome caused by diacylglycerol kinase epsilon deficiency. bioRxiv, 633867.

Azukaitis, K., Simkova, E., Majid, M. A., Galiano, M., Benz, K., Amann, K., ... & Schaefer, F. (2017). The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase ε. Journal of the American Society of Nephrology, 28(10), 3066-3075.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-DGKE Recombinant Antibody (7E1)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Mouse Anti-DGKE Recombinant Antibody (7E1) (CAT#: V2LY-0425-LY246)

Related Products

Mouse Anti-DGKE Recombinant Antibody (CBYCD-252) (CAT#: V2LY-0425-LY245)

Human Recombinant DGKE, Active protein, His Tag (CAT#: V2LY-0526-LY3562)

Mouse Anti-DGKE Recombinant Antibody (CBYCD-252) (CAT#: CBMAB-D0785-YC)

Human Recombinant DGKE, Active protein, GST Tag (CAT#: V2LY-0526-LY3561)

Mouse Anti-DGKE Recombinant Antibody (12K78) (CAT#: CBMAB-D0788-YC)

Mouse Anti-DGKE Recombinant Antibody (12K78) (CAT#: V2LY-0425-LY247)

Mouse Anti-DGKE Recombinant Antibody (7E1) (CAT#: V2LY-0425-LY246)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry